Přihlásit se Zaregistrujte se zdarma

EBITDA společnosti Kazia Therapeutics

Jaká je hodnota metriky EBITDA společnosti Kazia Therapeutics?

Hodnota metriky EBITDA společnosti Kazia Therapeutics Limited je -AUD$22.91

Jaká je definice metriky EBITDA?



EBITDA je zisk před odečtením úroků, daní, odpisů a amortizací udávající operační výkonnost společnosti.

Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.

EBITDA společností v sektoru Health Care sektor na ASX ve srovnání se společností Kazia Therapeutics

Čemu se věnuje společnost Kazia Therapeutics?

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

Firmy s metrikou ebitda podobnou společnosti Kazia Therapeutics



  • Hodnota metriky EBITDA společnosti Vtex je -$23.21
  • Hodnota metriky EBITDA společnosti Puxin je -¥23.19
  • Hodnota metriky EBITDA společnosti Corvus Gold je -CAD$23.08
  • Hodnota metriky EBITDA společnosti Corvus Gold je -CAD$23.08
  • Hodnota metriky EBITDA společnosti Hempfusion Wellness je -$23.06
  • Hodnota metriky EBITDA společnosti Clenergen je -$22.99
  • Hodnota metriky EBITDA společnosti Kazia Therapeutics je -AUD$22.91
  • Hodnota metriky EBITDA společnosti Shield Therapeutics Plc je -£22.90
  • Hodnota metriky EBITDA společnosti China Shun Ke Long je -¥22.90
  • Hodnota metriky EBITDA společnosti Sezzle je -$22.90
  • Hodnota metriky EBITDA společnosti Sezzle je -$22.90
  • Hodnota metriky EBITDA společnosti GreenBox POS je -$22.87
  • Hodnota metriky EBITDA společnosti Navya SA je -€22.86